Evidence map›Paper›PMID 39530517›Full record

ArticleFuture medicinal chemistry2024

New immunomodulatory anticancer quinazolinone-based thalidomide analogs: design, synthesis and biological evaluation.

Maged Mohammed Saleh Al Ward, Abdallah E Abdallah, Mohamed F Zayed, Rezk R Ayyad, Tamer M Abdelghany, Dina Abed Bakhotmah, Mohamed Ayman El-Zahabi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Synthesis, evaluation ofRSC advances · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maged Mohammed Saleh Al WardPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt.
Abdallah E AbdallahPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt.ORCID 0000-0003-2597-7419
Mohamed F ZayedPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt.
Rezk R AyyadPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt.
Tamer M AbdelghanyPharmacology & Toxicology Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, 11785, Egypt.
Dina Abed BakhotmahKing abdulaziz university Chemistry department, Kingdom of Saudi Arabia.
Mohamed Ayman El-ZahabiPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt.ORCID 0000-0003-4538-5840

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsDrug DesignQuinazolinonesThalidomideCaspase 8Cell ProliferationDrug Screening Assays, AntitumorHep G2 CellsHumansImmunologic FactorsImmunomodulating AgentsMolecular StructureStructure-Activity RelationshipTranscription Factor RelATumor Necrosis Factor-alphaVascular Endothelial Growth Factor AAntineoplastic AgentsCaspase 8Immunologic FactorsImmunomodulating AgentsQuinazolinonesThalidomideTranscription Factor RelATumor Necrosis Factor-alphaVascular Endothelial Growth Factor Aanticancerglutarimideimmunomodulationquinazolinonethalidomide

Identifiers

PMID39530517
PMCPMC11622738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.